Common Contracts
2 similar License Agreement contracts by Forma Therapeutics Holdings, Inc.,
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • May 29th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances) • New York
This [***] LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of December 28, 2018 (the “Effective Date”) by and among Forma Parent (solely for purposes of Articles 4, 5, 7 and 9) and Forma Inc. (as each such term is defined in Exhibit A), and Celgene Alpine Investment Company II, LLC, a Delaware limited liability company (“Celgene”). Forma Parent, Forma Inc. and Celgene are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • May 6th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances) • New York
This [***] LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of December 28, 2018 (the “Effective Date”) by and among Forma Parent (solely for purposes of Articles 4, 5, 7 and 9) and Forma Inc. (as each such term is defined in Exhibit A), and Celgene Alpine Investment Company II, LLC, a Delaware limited liability company (“Celgene”). Forma Parent, Forma Inc. and Celgene are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
